- Home
- KRMD vs IVA Comparison
KRMD vs IVA Comparison
Compare KRMD & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRMD
- IVA
- Stock Information
- Founded
- KRMD 1980
- IVA 2011
- Country
- KRMD United States
- IVA France
- Employees
- KRMD N/A
- IVA N/A
- Industry
- KRMD Medical/Dental Instruments
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- KRMD Health Care
- IVA Health Care
- Exchange
- KRMD Nasdaq
- IVA Nasdaq
- Market Cap
- KRMD 127.0M
- IVA 117.3M
- IPO Year
- KRMD N/A
- IVA 2020
- Fundamental
- Price
- KRMD $2.72
- IVA $1.89
- Analyst Decision
- KRMD Strong Buy
- IVA Strong Buy
- Analyst Count
- KRMD 3
- IVA 3
- Target Price
- KRMD $3.33
- IVA $18.00
- AVG Volume (30 Days)
- KRMD 96.6K
- IVA 14.4K
- Earning Date
- KRMD 11-06-2024
- IVA 09-25-2024
- Dividend Yield
- KRMD N/A
- IVA N/A
- EPS Growth
- KRMD N/A
- IVA N/A
- EPS
- KRMD N/A
- IVA N/A
- Revenue
- KRMD $30,817,017.00
- IVA $20,652,523.00
- Revenue This Year
- KRMD $15.46
- IVA N/A
- Revenue Next Year
- KRMD $17.47
- IVA $469.85
- P/E Ratio
- KRMD N/A
- IVA N/A
- Revenue Growth
- KRMD 4.70
- IVA N/A
- 52 Week Low
- KRMD $1.98
- IVA $1.53
- 52 Week High
- KRMD $3.09
- IVA $4.75
- Technical
- Relative Strength Index (RSI)
- KRMD 58.09
- IVA 45.86
- Support Level
- KRMD $2.42
- IVA $1.60
- Resistance Level
- KRMD $2.74
- IVA $1.92
- Average True Range (ATR)
- KRMD 0.14
- IVA 0.13
- MACD
- KRMD -0.01
- IVA -0.00
- Stochastic Oscillator
- KRMD 59.41
- IVA 54.46
About KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.